Skip to content
value.today

Endurance Biotech, Inc.

Total raised
$36 M
3 rounds on record
Latest round
$15 M
Jan 2018
First round on record
Aug 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Endurance Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2018$15 MNo. 3$10 to $50 million

Endurance Biotech, Inc.: Raise no. 3, Jan 2018

Investors in this round

53 investors had bought by the notice of Feb 2, 2018: 53 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $16 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fauad Hasan · Executive Officer, Director
  • Wajdie Ahmad · Executive Officer
  • ALEXEY KONOV, Ph.D. · Director
  • David Ramsay · Director
  • Dennis Huang · Director
  • Jonathan Lim, M.D. · Director
  • Tom Albright · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Fauad Hasan, Chief executive officer. Source: SEC Form D, newest notice filed Feb 2, 2018. Read the notice at the SEC.

equitySEC
Dec 2016$12 MNo. 2$10 to $50 million

Endurance Biotech, Inc.: Raise no. 2, Dec 2016

Investors in this round

32 investors had bought by the notice of Apr 19, 2017: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fauad Hasan · Executive Officer, Director
  • Michael Jarpe · Executive Officer
  • Wajdie Ahmad · Executive Officer
  • ALEXEY KONOV, Ph.D. · Director
  • David Ramsay · Director
  • Dennis Huang · Director
  • Jonathan Lim, M.D. · Director
  • Tom Albright · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Fauad Hasan, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 19, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$9 MNo. 1$2 to $10 million

Endurance Biotech, Inc.: Raise no. 1, Aug 2015

Investors in this round

39 investors had bought by the notice of Sep 15, 2015: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$274,800
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fauad Barry Hasan · Executive Officer, Director
  • Kenton Barry Abel · Executive Officer
  • Michael Barry Jarpe · Executive Officer
  • Wajdie Barry Ahmad · Executive Officer
  • David Barry Ramsay · Director
  • Dennis Barry Huang · Director
  • Leonard Barry Brandt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ascendiant Capital Markets, LLC (CRD 152912) · Irvine, CaliforniaSold in CA, NV, TX
  • Brian Davies · broker-dealer Ascendiant Capital Markets, LLC (CRD 152912) · Irvine, CaliforniaSold in AZ, CA, NV, TX
  • Chris Gayde · broker-dealer Ascendiant Capital Markets, LLC (CRD 152912) · Irvine, CaliforniaSold in CA, NV, TX

Remarks in the notice

  • On fees: “Subject to future contingencies, Ascendiant Capital Markets, LLC may also receive warrants to acquire up to 200,000 shares of common stock.”

Signed by Kenton B. Abel, Corporate Secretary. Source: SEC Form D and 1 amendment, newest notice filed Sep 15, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Endurance Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2018).

    SEC Form D · Feb 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2018

That is all the official record says: Endurance Biotech, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Endurance Biotech, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 53 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Endurance Biotech, Inc.
NameRoleNamed in
Fauad HasanExecutive officerFeb 2018
Wajdie AhmadExecutive officerFeb 2018
Michael JarpeExecutive officerApr 2017
Fauad Barry HasanExecutive officerSep 2015
Kenton Barry AbelExecutive officerSep 2015
Michael Barry JarpeExecutive officerSep 2015
Wajdie Barry AhmadExecutive officerSep 2015
ALEXEY KONOV, Ph.D.DirectorFeb 2018
David RamsayDirectorFeb 2018
Dennis HuangDirectorFeb 2018
Fauad HasanDirectorFeb 2018
Jonathan Lim, M.D.DirectorFeb 2018
Tom AlbrightDirectorFeb 2018
David Barry RamsayDirectorSep 2015
Dennis Barry HuangDirectorSep 2015
Fauad Barry HasanDirectorSep 2015
Leonard Barry BrandtDirectorSep 2015